Matthew Eckman joined Schultz Collins in August of 2018. He participates in every aspect of portfolio supervision for the practice’s clients and brings new academic insights both to the financial planning process and to the provision of client services. He is a member of the Financial Planning Association and currently pursuing the CERTIFIED FINANCIAL PLANNER (CFP®) certification.
Prior to joining Schultz Collins, Mr. Eckman worked for almost two decades in various capacities in the healthcare sector. He served as the Head of Financial Risk for the multi‐billion‐dollar procurement portfolio of global biotechnology firms Genentech and F. Hoffmann‐La Roche. He also served as a biotechnology equity research analyst at U.S. investment bank Piper Jaffray, a management consultant on competitive intelligence at Fuld + Company, and as a cancer research scientist with the Howard Hughes Medical Institute at the Massachusetts Institute of Technology.
Mr. Eckman has spoken nationally and internationally on the topics of corporate financial risk and the impact of private equity investments on corporate financial health and stability. His research contributions have been published in Cancer Research, Molecular and Cellular Biology, Journal of Biological Chemistry, and Molecular Cell.
Mr. Eckman holds a Bachelor of Science degree in Biochemistry and Molecular Biology (magna cum laude and with high honors) from the University of Georgia and a Master of Science degree in Financial Planning (with highest honors) from Golden Gate University.
In his spare time, Mr. Eckman enjoys spending time with his wife and young daughter, visiting wine country, and traveling the world. He looks forward to resuming old hobbies, like photography and playing golf, and tackling new ones, like woodworking.